Vedanta Biosciences, Inc. Vedanta Biosciences, Inc.

  • Home
  • About
    • Overview
    • Team
    • Scientific Co-Founders and Advisors
    • Board of Directors
  • Pipeline
    • Overview
    • VE800
    • VE303
    • VE202
    • VE416
    • VE707
    • Partnerships
    • Intellectual Property
  • Clinical Trials
    • VE303
    • VE800
    • VE416
    • VE202
  • Platform
    • Overview
    • How Our Drugs Work
    • Publications
  • News & Media
    • Overview
    • Press Releases
    • In The News
  • Careers
  • Contact
News & Media

News & Media

  • Overview
  • Press Releases
  • In The News

Press Releases

Sep 23, 2019

Vedanta Biosciences Announces $16.6 Million Series C-2 Financing

Jul 1, 2019

Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

Jun 25, 2019

Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35

May 13, 2019

Vedanta Biosciences Closes Extended $45.5 Million Series C Financing

May 7, 2019

Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings

Jan 23, 2019

Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal for its Immuno-oncology Candidate, VE800

Dec 24, 2018

Vedanta Biosciences Raises $27 Million Series C Financing to Advance Clinical Pipeline of Microbiome-Derived Product Candidates

Dec 17, 2018

Vedanta Biosciences Initiates Phase 2 Study for Lead Rationally-Defined Bacterial Consortium Product Candidate, VE303

Dec 10, 2018

Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers

Nov 27, 2018

Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for Inflammatory Bowel Disease

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »
RSS Feed
© 2021 Vedanta Biosciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap